Given the FDA's April 2026 proposal with a comment period closing June 29, 2026, this a real question for anyone starting a multi-month compounded GLP-1 program right now
Large, long-term outcome studies show that GLP-1 therapies improve outcomes and reduce the incidence of diseases closely linked to inflammation, including osteoarthritis, cardiovascular disease, fatty liver disease, chronic kidney disease, Alzheimers, and autoimmune conditions
This will allow you to feel fuller for longer and curb cravings. *These statements have not been evaluated by the Food and Drug Administration
[6] Crucially for weight management, these medications act on appetite-regulating centres in the hypothalamus, reducing hunger signals and increasing satiety
Claims management software can catch these before submission, but coders still need a solid grasp of what HCPCS Code J1815 covers and when it applies